

§ 520.1380

(4) Examination of vaginal smears is recommended to confirm detection of proestrus.

(5) Do not administer for more than two consecutive treatments.

(6) Once therapy is started, the animal should be confined for 3 to 8 days or until cessation of bleeding, since dogs in proestrus accept a male.

(7) Do not use prior to or during first estrus cycle.

(8) Do not use in pregnant animals.

(9) Do not use in the presence of a disease of the reproductive system or with mammary tumors.

(10) Should estrus occur within 30 days after cessation of treatment, mating should be prevented.

(11) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 520.1380 Methocarbamol tablets.

(a) *Chemical name.* 3-(O-Methoxyphenoxy)-1,2-propanediol 1-carbamate.

(b) *Specifications.* Each tablet contains 500 milligrams of methocarbamol.

(c) *Sponsor.* See No. 000031 in § 510.600(c) of this chapter.

(d) *Conditions of use.* (1) The drug is administered to dogs and cats as an adjunct to therapy for acute inflammatory and traumatic conditions of the skeletal muscles in order to reduce muscular spasms.

(2) Dosage is based upon severity of symptoms and response noted. The usual initial dose in 60 milligrams per pound of body weight in two or three equally divided doses followed by 30 to 60 milligrams per pound of body weight each following day, usually not to exceed 14 to 21 days.

(3) For use only by or on the order of a licensed veterinarian.

§ 520.1390 (S)-methoprene.

(a) *Specifications.* Each capsule contains 154, 308, or 462 milligrams (mg) of (S)-methoprene.

(b) *Sponsor.* See No. 011536 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) *Conditions of use—(1) Amount.* Capsules are given orally, once per week at the recommended minimum dosage of

21 CFR Ch. I (4–1–02 Edition)

10 mg of (S)-methoprene per pound of body weight (22 mg/kilograms).

(2) *Indications for use.* For oral use in dogs, 9 weeks of age and older and 4 pounds body weight or greater, for the prevention and control of flea populations. (S)-methoprene prevents and controls flea populations by preventing the development of flea eggs but does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

[65 FR 20730, Apr. 18, 2000]

§ 520.1408 Methylprednisolone tablets.

(a) *Specifications.* Each table contains 1, 2, or 4 milligrams of methylprednisolone.

(b) *Sponsor.* See No. 000009 in § 510.600(c) of this chapter for use of 1- and 4-milligram tablets; see No. 000010 for use of 1- and 2-milligram tablets.

(c) *NAS/NRC status.* The conditions of use have been NAS/NRC reviewed and found effective. NADA's for approval of drugs for these conditions of use need not include effectiveness data specified by § 514.111 of this chapter, but may require bioequivalency and safety information.

(d) *Special consideration.* (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

(2) Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, or cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind.

(3) Anti-inflammatory action of corticosteroids may mask signs of infection.